Aastha Pal

This paper presents a high-throughput platform for screening peptide-guided protein degraders in mammalian cells, demonstrating their ability to reduce target protein abundance and function.

The paper shows that T cells engineered with IL-9R have better tissue infiltration, stemness, and anti-tumor activity compared to those with an orthogonal IL-9 receptor, due to stronger and more specific JAK/STAT signaling.

SCAN-ACT identifies and prioritizes T cell therapy targets for solid tumors using single-cell transcriptomics and multi-omics data, validating targets through experimental methods.